Skip to content

NeoGenomics NEO Weighted Average Exercise Price of Outstanding Options

Weighted Average Exercise Price of Outstanding Options at other companies

CareDx logo
CareDxCDNA
$20.62-1.9%
BillionToOne, Inc.
 logo
BillionToOne, Inc. BLLN
$14.61
Guardant Health logo
Guardant HealthGH
Natera, Inc. logo
Natera, Inc.NTRA

Other financials

Income statement

See full
Revenue$186.7M+11.1%
Gross profit$80.9M+10.4%
Operating income-$18.2M+34.4%
Net income-$17.1M+34.0%
EPS (diluted)-$0.13+35.0%

Balance sheet

See full
Cash & equivalents$146.1M-57.8%
Total debt$66.3M+5.3%
Total equity$828.8M-6.7%
Total assets$1.3B-15.9%

Cash flow

See full
Operating cash flow-$8.1M+67.9%
CapEx$5.0M+11.1%
Free cash flow-$13.1M+56.0%

Valuation

See full
Market cap$1.68B+86.5%
Enterprise value$1.6B+159%
P/S2.3×+0.9×

Profitability

See full
Gross margin43.2%-1.1pp
Operating margin-14.2%+1.1pp
Net margin-13.3%+2.4pp
FCF margin-4.9%

Returns & leverage

See full
Return on equity-11.6%+6.2pp
Debt / equity0.1×0.0×
Current ratio4.4×+2.4×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.

The official record: NeoGenomics’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about NeoGenomics's weighted average exercise price of outstanding options.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NeoGenomics's weighted average exercise price of outstanding options?
NeoGenomics (NEO) reported weighted average exercise price of outstanding options of $12.76 in Q1 2026.
How has NeoGenomics's weighted average exercise price of outstanding options changed year-over-year?
NeoGenomics's weighted average exercise price of outstanding options decreased by 11.1% year-over-year, from $14.36 to $12.76.
What does weighted average exercise price of outstanding options mean?
This metric calculates the average price at which holders of outstanding stock options can purchase company shares. It provides context on the 'in-the-money' status of employee compensation packages. When compared to the current market price, it helps assess the alignment between employee incentives and shareholder value.